*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Atlanta, GA | Posted: April 23, 2015
Jerry Grillo
Communications Officer II
Parker H. Petit Institute for
Bioengineering and Bioscience
Summary Sentence:
Study will focus on drug delivery for breast cancer patients
Full Summary:
Study will focus on drug delivery for breast cancer patients
Susan ThomasSusan Thomas, faculty member of the Parker H. Petit Institute for Bioengineering and Bioscience, was recently awarded a three-year, $450,000 grant from the Susan G. Komen Foundation.
The grant – the first Komen award to the Georgia Institute of Technology – will be used to study how targeted delivery technology developed in the Thomas lab can be used to deliver drugs to sentinel lymph nodes in breast cancer patients, a form of immunotherapy.
When cancer cells spread from a primary tumor in the breast, their first stop in the lymph nodes are typically the sentinel lymph nodes. Sentinel lymph nodes are the first lymph nodes to which cancer cells are most likely to spread from a primary tumor. Thomas has been exploring how targeted delivery of therapeutics could promote anti-tumor immunity and hinder tumor growth.
“Immunotherapy has the potential to treat tumors that we can’t actually see,” says Thomas, assistant professor in the Woodruff School of Mechanical Engineering, who is also affiliated with the Coulter Department of Biomedical Engineering.
“But our immune system can see them,” she adds. “So this is a way of teaching our immune system to find the cancer and kill it, or prevent the disease occurrence. If we could teach our immune systems to kill, say, a breast tumor or breast cancer metastases or any other malignant tumor, that would be very beneficial in the long term.”
CONTACT:
Jerry Grillo
Communications Officer II
Parker H. Petit Institute for
Bioengineering and Bioscience
